Although only 10-15%of liver cancers are cholangiocarcinomas(CCAs),which derive from the epithelial cells of the biliary tree,these cancers constitute a serious and growing health problem worldwide.The rate of mortali...Although only 10-15%of liver cancers are cholangiocarcinomas(CCAs),which derive from the epithelial cells of the biliary tree,these cancers constitute a serious and growing health problem worldwide.The rate of mortality due to this tumor is very high because CCA usually appears in aged people and very often,in more than 70%of cases,are diagnosed late because of:(I)their anatomical localization in a big organ like the liver;(II)the lack of specific symptoms during most time of their development;and(III)the absence of available accurate,specific and sensitive biomarkers(1).These characteristics reduce the rate of success of surgical resection,which is the only curative option for CCA patients,because the response of this aggressive cancer to the available pharmacological armamentarium is extremely feeble(2).This justifies the interest of many groups to identify non-invasive markers to achieve early diagnosis that also permit to distinguish CCA from non-malignant biliary diseases and from hepatocellular carcinoma(HCC),the most frequent liver cancer,which derives from hepatocytes(3).展开更多
Cholangiocarcinoma(CCA)is the second most frequent primary malignant neoplasm of the hepatobiliary system.Unfortunately,CCA is often diagnosed at an advanced stage,when potentially curative surgical treatments are not...Cholangiocarcinoma(CCA)is the second most frequent primary malignant neoplasm of the hepatobiliary system.Unfortunately,CCA is often diagnosed at an advanced stage,when potentially curative surgical treatments are not recommended.The probability of achieving complete resection in patients who undergo surgery is about 25%(1)and even when complete tumor removal is achieved,the risk of recurrence is greater than 50%.Identification and validation of reliable biomarkers is crucial for the early detection,accurate diagnosis,appropriate staging/prognosis,therapy selection and effective monitoring of patients with biliary tract cancers(BTCs)(Figure 1).Achieving early diagnosis remains a challenge to improve survival and,although many promising biomarkers have been identified(2),to date none have reached clinical practice.展开更多
基金Carlos III Institute of Health,Spain(PI16/00598 and PI19/00819)co-financed by European Regional Development FundMinistry of Science and Innovation,Spain(SAF2016-75197-R)Asociación Espanola Contra el Cancer,Spain(AECC-Cancer raros 2017/2020)and Centro Internacional sobre el Envejecimiento,Spain(OLD-HEPAMARKER,0348_CIE_6_E)co-financed with European Union ERDF funds.
文摘Although only 10-15%of liver cancers are cholangiocarcinomas(CCAs),which derive from the epithelial cells of the biliary tree,these cancers constitute a serious and growing health problem worldwide.The rate of mortality due to this tumor is very high because CCA usually appears in aged people and very often,in more than 70%of cases,are diagnosed late because of:(I)their anatomical localization in a big organ like the liver;(II)the lack of specific symptoms during most time of their development;and(III)the absence of available accurate,specific and sensitive biomarkers(1).These characteristics reduce the rate of success of surgical resection,which is the only curative option for CCA patients,because the response of this aggressive cancer to the available pharmacological armamentarium is extremely feeble(2).This justifies the interest of many groups to identify non-invasive markers to achieve early diagnosis that also permit to distinguish CCA from non-malignant biliary diseases and from hepatocellular carcinoma(HCC),the most frequent liver cancer,which derives from hepatocytes(3).
文摘Cholangiocarcinoma(CCA)is the second most frequent primary malignant neoplasm of the hepatobiliary system.Unfortunately,CCA is often diagnosed at an advanced stage,when potentially curative surgical treatments are not recommended.The probability of achieving complete resection in patients who undergo surgery is about 25%(1)and even when complete tumor removal is achieved,the risk of recurrence is greater than 50%.Identification and validation of reliable biomarkers is crucial for the early detection,accurate diagnosis,appropriate staging/prognosis,therapy selection and effective monitoring of patients with biliary tract cancers(BTCs)(Figure 1).Achieving early diagnosis remains a challenge to improve survival and,although many promising biomarkers have been identified(2),to date none have reached clinical practice.
